Heparin-induced thrombocytopenia future or investigational therapies
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia future or investigational therapies |
|
FDA on Heparin-induced thrombocytopenia future or investigational therapies |
|
CDC on Heparin-induced thrombocytopenia future or investigational therapies |
|
Heparin-induced thrombocytopenia future or investigational therapies in the news |
|
Blogs on Heparin-induced thrombocytopenia future or investigational therapies |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]
Overview
Future therapies involve use of factor X inhibitors or direct thrombin inhibitors. The data is currently not mature enough to make any clinical recommendations.
Future or Investigational Therapies
Future therapies for HIT focus on use of new oral anticoagulants.[1] Director factor X inhibitors and newer direct thrombin inhibitors are being studied, but the data is currently in its infancy. Cost-effectiveness analyses will need to be done to determine whether it is appropriate to use these new agents.
References
- ↑ Harenberg J, Marx S, Krejczy M, Wehling M (2012). "New anticoagulants - promising and failed developments". Br J Pharmacol. 165 (2): 363–72. doi:10.1111/j.1476-5381.2011.01578.x. PMC 3268190. PMID 21740405.